when it comes to Pharma or healthcare companies they always needs to keep certain percentage of their revenue to support Research and development. we checked some of those to see which companies are spending the most.
AbbVie top the list spending $7.1 Billion which counts for as much as 14% of it’s Revenue.
Here is the full list :
Here is the same information in table format:
| Company | Drug | Years of Sales Data | Price-driven Revenue | Lost R&D Spending |
| Astellas Pharma | Xtandi | 8 | $1,343 | -$227 |
| Eli Lilly | Alimta | 10 | $1,478 | -$384 |
| Novo Nordisk | Victoza | 10 | $1,809 | -$263 |
| Takeda | Entyvio | 6 | $2,007 | -$320 |
| GlaxoSmithKline | Benlysta | 9 | $2,011 | -$255 |
| AstraZeneca | Lynparza | 6 | $2,721 | -$687 |
| Merck | Keytruda | 6 | $3,074 | -$806 |
| Sanofi | Aubagio | 8 | $3,225 | -$489 |
| Roche | Avastin | 10 | $4,897 | -$1,193 |
| Pfizer | Xeljanz | 8 | $5,557 | -$895 |
| Gilead Sciences | Truvada | 10 | $5,738 | -$916 |
| Bristol Myers Squibb | Orencia | 10 | $6,789 | -$1,792 |
| Biogen | Tysabri | 10 | $7,201 | -$1,473 |
| Novartis | Gilenya | 10 | $7,980 | -$1,508 |
| Johnson & Johnson | Stelara | 10 | $13,764 | -$2,932 |
| Amgen | Enbrel | 10 | $21,300 | -$3,848 |
| AbbVie | Humira | 10 | $48,994 | -$7,184 |
Do also check out our chart section.
